China Biologic Products, Inc.
by Tracey RyniecJuly 12, 2010 | Comments : 0 Recommended this article: (0)
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at firstname.lastname@example.org or call 800-767-3771 ext. 9339.
It also is still a Zacks #1 Rank (strong buy) stock despite missing on earnings for the first quarter by a penny.
Revenue Jumped 28.1% in the First Quarter
On May 17, China Biologic, which produces and manufactures plasma products for hospitals and other medical facilities, announced first quarter results which saw revenue climb to $27.1 million from $21.1 million in the first quarter of 2009.
The revenue growth came from general price increases ranging from 3.1% to 118.3% across the company's products.
Plasma continues to be in short supply in China so the company has pricing power. However, the price increases are not expected to continue at the same pace. China Biologic anticipates modest price increases on a few select products but is not factoring those into its guidance.
Outlook for 2010
China Biologic is optimistic about 2010 due to tight supply in China's plasma industry and continued expansion of its operations through acquisitions. It recently got approval to build two new plasma stations in Shandong.
2010 revenue is expected in the range of $142 million to $149 million which is about 25% higher than 2009's revenue of $119 million. The first quarter is historically the weakest quarter of the year for the company due to the Chinese New Year.
Zacks Consensus Estimates Rise
China Biologic is scheduled to report first quarter results on Aug 16. The Zacks Consensus has risen to 44 cents from 39 cents in the last 60 days. There are only 2 estimates on the company.
The full year has jumped by 30 cents to $1.68 in the last 2 months.
Earnings per share are expected to grow 21%.
China Biologic is still cheap. It is trading at 7.2x forward earnings which is cheaper than last April when it traded at 7.8x.
The company has a price-to-sales ratio of 2.3 which is below the industry average of 4.5.
It also has a stellar 1-year return on equity (ROE) of 39.6% whereas the industry is just at 7.1%.
Update to Previous Value Zacks Rank Buy Stocks
Sanderson Farms, Inc. (SAFM) is going to get a boost by resuming chicken shipments to Russia. As it stands, it is already pretty cheap, trading at just 9x forward earnings, well under the industry average of 14.1 and easily in the range of a traditional "value" stock. Read the full article.
Imagine easily beating estimates for the second quarter in a row and posting record revenue only to have your stock sell off 12% on the news? Such is the reality for Xyratex Limited (XRTX), the British-based provider of enterprise class data storage subsystems and network technology, which reported second quarter results on June 30. Read the full article.
Read the full reports :
Please login to Zacks.com or register to post a comment.